- Home
- TNXP vs DRUG Comparison
TNXP vs DRUG Comparison
Compare TNXP & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- DRUG
- Stock Information
- Founded
- TNXP 2007
- DRUG 2019
- Country
- TNXP United States
- DRUG United States
- Employees
- TNXP N/A
- DRUG N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- DRUG Pharmaceuticals and Biotechnology
- Sector
- TNXP Health Care
- DRUG Health Care
- Exchange
- TNXP Nasdaq
- DRUG Nasdaq
- Market Cap
- TNXP 335.6M
- DRUG 345.6M
- IPO Year
- TNXP N/A
- DRUG N/A
- Fundamental
- Price
- TNXP $22.41
- DRUG $55.20
- Analyst Decision
- TNXP Buy
- DRUG Strong Buy
- Analyst Count
- TNXP 1
- DRUG 9
- Target Price
- TNXP $70.00
- DRUG $81.67
- AVG Volume (30 Days)
- TNXP 1.1M
- DRUG 90.8K
- Earning Date
- TNXP 11-11-2025
- DRUG 08-11-2025
- Dividend Yield
- TNXP N/A
- DRUG N/A
- EPS Growth
- TNXP N/A
- DRUG N/A
- EPS
- TNXP N/A
- DRUG N/A
- Revenue
- TNXP $9,831,000.00
- DRUG N/A
- Revenue This Year
- TNXP $14.79
- DRUG N/A
- Revenue Next Year
- TNXP $933.49
- DRUG N/A
- P/E Ratio
- TNXP N/A
- DRUG N/A
- Revenue Growth
- TNXP N/A
- DRUG N/A
- 52 Week Low
- TNXP $6.76
- DRUG $0.94
- 52 Week High
- TNXP $130.00
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- TNXP 30.44
- DRUG 51.91
- Support Level
- TNXP $23.60
- DRUG $48.90
- Resistance Level
- TNXP $29.19
- DRUG $61.72
- Average True Range (ATR)
- TNXP 1.63
- DRUG 4.26
- MACD
- TNXP 0.12
- DRUG -0.52
- Stochastic Oscillator
- TNXP 5.31
- DRUG 35.95
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.